{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:17:42Z","timestamp":1777951062719,"version":"3.51.4"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Department of Clinical Science"},{"name":"Intervention and Technology"},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Karolinska Institutet Diabetes Theme Center"},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Heart and Lung Foundation"},{"name":"Njurfonden and Westmans Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The role of erythroferrone, a hormone synthesized in erythroid cells that suppresses hepatic production of hepcidin to increase systemic iron availability during erythropoiesis expansion, has not been sufficiently characterized in chronic kidney disease (CKD). Therefore, we evaluated its determinants and its association with mortality risk in patients with CKD stages 3\u20135.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this cross-sectional study with longitudinal follow-up, erythroferrone, hepcidin, ferritin, transferrin saturation (TSAT), C-reactive protein (CRP) and nutritional status were assessed in 377 CKD patients [92 patients with CKD stages 3\u20134, 210 non-dialysed patients with CKD stage 5 and 75 patients on peritoneal dialysis (PD)]. Regression analyses were performed to investigate the association between erythroferrone and relevant variables. The association between erythroferrone and mortality risk was analysed using Fine\u2013Gray analysis, accounting for kidney transplantation as a competing risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Erythroferrone, hepcidin and ferritin were higher in PD patients and in CKD 5 patients as compared with CKD 3\u20134 patients, whereas the hepcidin-to-ferritin ratio did not differ between the cohorts. In linear regression analysis, erythroferrone was positively associated with the reticulocyte count, CRP and CKD severity and negatively associated with TSAT and the hepcidin-to-ferritin ratio (and hepcidin). Further adjustment for erythropoiesis-stimulating agents (ESAs) revealed that erythroferrone no longer showed an association with the severity of CKD or CRP levels. Finally, erythroferrone was linked to both all-cause mortality and cardiovascular mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Erythroferrone in CKD patients associated with the reticulocyte count and ESA dose and was inversely correlated with the hepcidin-to-ferritin ratio and TSAT, while its relationship with CKD stage may reflect ESA therapy. Higher circulating erythroferrone levels are associated with an increased mortality risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ckj\/sfag075","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T12:40:49Z","timestamp":1772800849000},"source":"Crossref","is-referenced-by-count":0,"title":["Erythroferrone is associated with the hepcidin-to-ferritin ratio and cardiovascular mortality in chronic kidney disease"],"prefix":"10.1093","volume":"19","author":[{"given":"Kristin Danielson","family":"Pistis","sequence":"first","affiliation":[{"name":"Intervention and Technology, Karolinska Institutet Renal Medicine and Baxter Novum, Department of Clinical Science, , Stockholm ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0536-5327","authenticated-orcid":false,"given":"Abdul Rashid","family":"Qureshi","sequence":"additional","affiliation":[{"name":"Intervention and Technology, Karolinska Institutet Renal Medicine and Baxter Novum, Department of Clinical Science, , Stockholm ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soheir","family":"Beshara","sequence":"additional","affiliation":[{"name":"Karolinska Institutet Department of Molecular Medicine and Surgery, , Stockholm ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bengt","family":"Lindholm","sequence":"additional","affiliation":[{"name":"Intervention and Technology, Karolinska Institutet Renal Medicine and Baxter Novum, Department of Clinical Science, , Stockholm ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Stenvinkel","sequence":"additional","affiliation":[{"name":"Intervention and Technology, Karolinska Institutet Renal Medicine and Baxter Novum, Department of Clinical Science, , Stockholm ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6501-8293","authenticated-orcid":false,"given":"Peter","family":"B\u00e1r\u00e1ny","sequence":"additional","affiliation":[{"name":"Intervention and Technology, Karolinska Institutet Renal Medicine and Baxter Novum, Department of Clinical Science, , Stockholm ,","place":["Sweden"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"2026050404514652300_bib1","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD","volume":"23","author":"Babitt","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2026050404514652300_bib2","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12882-018-1021-3","article-title":"Association of different iron deficiency cutoffs with adverse outcomes in chronic kidney disease","volume":"19","author":"Eisenga","year":"2018","journal-title":"BMC Nephrol"},{"key":"2026050404514652300_bib3","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/sj.ki.5000105","article-title":"Association of anemia with outcomes in men with moderate and severe chronic kidney disease","volume":"69","author":"Kovesdy","year":"2006","journal-title":"Kidney Int"},{"key":"2026050404514652300_bib4","doi-asserted-by":"publisher","first-page":"3646","DOI":"10.1182\/blood-2014-01-550467","article-title":"Targeted disruption of hepcidin in the liver recapitulates the hemochromatotic phenotype","volume":"123","author":"Zumerle","year":"2014","journal-title":"Blood"},{"key":"2026050404514652300_bib5","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1182\/blood-2003-03-0672","article-title":"Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation","volume":"102","author":"Ganz","year":"2003","journal-title":"Blood"},{"key":"2026050404514652300_bib6","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1126\/science.1104742","article-title":"Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization","volume":"306","author":"Nemeth","year":"2004","journal-title":"Science"},{"key":"2026050404514652300_bib7","doi-asserted-by":"publisher","first-page":"e99781","DOI":"10.1371\/journal.pone.0099781","article-title":"The relation of hepcidin to iron disorders, inflammation and hemoglobin in chronic kidney disease","volume":"9","author":"Mercadal","year":"2014","journal-title":"PLoS One"},{"key":"2026050404514652300_bib8","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/ki.2009.21","article-title":"Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease","volume":"75","author":"Ashby","year":"2009","journal-title":"Kidney Int"},{"key":"2026050404514652300_bib9","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1182\/blood-2018-06-857995","article-title":"Erythroferrone inhibits the induction of hepcidin by BMP6","volume":"132","author":"Arezes","year":"2018","journal-title":"Blood"},{"key":"2026050404514652300_bib10","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood.2019002620","article-title":"Erythroferrone lowers hepcidin by sequestering BMP2\/6 heterodimer from binding to the BMP type I receptor ALK3","volume":"135","author":"Wang","year":"2020","journal-title":"Blood"},{"key":"2026050404514652300_bib11","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/ng.2996","article-title":"Identification of erythroferrone as an erythroid regulator of iron metabolism","volume":"46","author":"Kautz","year":"2014","journal-title":"Nat Genet"},{"key":"2026050404514652300_bib12","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1182\/blood-2014-06-584607","article-title":"Erythroferrone contributes to recovery from anemia of inflammation","volume":"124","author":"Kautz","year":"2014","journal-title":"Blood"},{"key":"2026050404514652300_bib13","doi-asserted-by":"publisher","first-page":"11968","DOI":"10.1074\/jbc.M111.336834","article-title":"Myonectin (CTRP15), a novel myokine that links skeletal muscle to systemic lipid homeostasis","volume":"287","author":"Seldin","year":"2012","journal-title":"J Biol Chem"},{"key":"2026050404514652300_bib14","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1046\/j.1523-1755.1998.00812.x","article-title":"Factors predicting malnutrition in hemodialysis patients: a cross-sectional study","volume":"53","author":"Qureshi","year":"1998","journal-title":"Kidney Int"},{"key":"2026050404514652300_bib15","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/sj.ki.5002585","article-title":"A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease","volume":"73","author":"Fouque","year":"2008","journal-title":"Kidney Int"},{"key":"2026050404514652300_bib16","doi-asserted-by":"publisher","first-page":"101306","DOI":"10.1016\/j.xcrm.2023.101306","article-title":"FK506 bypasses the effect of erythroferrone in cancer cachexia skeletal muscle atrophy","volume":"4","author":"Mina","year":"2023","journal-title":"Cell Rep Med"},{"key":"2026050404514652300_bib17","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3390\/jcm8040523","article-title":"Serum Erythroferrone levels associate with mortality and cardiovascular events in hemodialysis and in CKD patients: a two cohorts study","volume":"8","author":"Spoto","year":"2019","journal-title":"J Clin Med"},{"key":"2026050404514652300_bib18","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3747\/pdi.2013.00064","article-title":"Increased levels of modified advanced oxidation protein products are associated with central and peripheral blood pressure in peritoneal dialysis patients","volume":"35","author":"Xu","year":"2015","journal-title":"Perit Dial Int"},{"key":"2026050404514652300_bib19","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1046\/j.1523-1755.1999.00422.x","article-title":"Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure","volume":"55","author":"Stenvinkel","year":"1999","journal-title":"Kidney Int"},{"key":"2026050404514652300_bib20","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1177\/0003319713483000","article-title":"Subclinical atherosclerosis, endothelial function, and serum inflammatory markers in chronic kidney disease stages 3 to 4","volume":"65","author":"Ghanavatian","year":"2014","journal-title":"Angiology"},{"key":"2026050404514652300_bib21","doi-asserted-by":"publisher","first-page":"4888","DOI":"10.1002\/jcp.30247","article-title":"Erythroferrone structure, function, and physiology: iron homeostasis and beyond","volume":"236","author":"Srole","year":"2021","journal-title":"J Cell Physiol"},{"key":"2026050404514652300_bib22","first-page":"3853","article-title":"Erythroferrone overexpression mitigates anemia and improves kidney function in a mouse model of CKD","volume-title":"Blood","author":"Czaya","year":"2024"},{"key":"2026050404514652300_bib23","doi-asserted-by":"crossref","first-page":"e190018","DOI":"10.1172\/jci.insight.190018","article-title":"Transgenic augmentation of erythroferrone in mice ameliorates anemia in adenine-induced chronic kidney disease","volume":"10","author":"Czaya","year":"2025","journal-title":"JCI Insight"},{"key":"2026050404514652300_bib24","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.3324\/haematol.2017.181743","article-title":"Levels of the erythropoietin-responsive hormone erythroferrone in mice and humans with chronic kidney disease","volume":"103","author":"Hanudel","year":"2018","journal-title":"Haematologica"},{"key":"2026050404514652300_bib25","doi-asserted-by":"publisher","first-page":"e0151601","DOI":"10.1371\/journal.pone.0151601","article-title":"Associations among erythroferrone and biomarkers of erythropoiesis and iron metabolism, and treatment with long-term erythropoiesis-stimulating agents in patients on hemodialysis","volume":"11","author":"Honda","year":"2016","journal-title":"PLoS One"},{"key":"2026050404514652300_bib26","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/j.1365-2141.1994.tb08320.x","article-title":"rh-erythropoietin stimulates immature reticulocyte release in man","volume":"87","author":"Major","year":"1994","journal-title":"Br J Haematol"},{"key":"2026050404514652300_bib27","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1093\/ndt\/18.2.370","article-title":"Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients","volume":"18","author":"Chuang","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"2026050404514652300_bib28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.semnephrol.2016.02.001","article-title":"Iron balance and the role of hepcidin in chronic kidney disease","volume":"36","author":"Ganz","year":"2016","journal-title":"Semin Nephrol"},{"key":"2026050404514652300_bib29","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1159\/000312381","article-title":"Determinants of hepcidin in patients on maintenance hemodialysis: role of inflammation","volume":"31","author":"Kuragano","year":"2010","journal-title":"Am J Nephrol"},{"key":"2026050404514652300_bib30","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/jmedgenet-2011-100061","article-title":"Association of HFE and TMPRSS6 genetic variants with iron and erythrocyte parameters is only in part dependent on serum hepcidin concentrations","volume":"48","author":"Traglia","year":"2011","journal-title":"J Med Genet"},{"key":"2026050404514652300_bib31","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1182\/blood-2010-04-281360","article-title":"Transferrin receptor 2 is a component of the erythropoietin receptor complex and is required for efficient erythropoiesis","volume":"116","author":"Forejtnikova","year":"2010","journal-title":"Blood"},{"key":"2026050404514652300_bib32","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/ajh.24417","article-title":"Hematopoietic deletion of transferrin receptor 2 in mice leads to a block in erythroid differentiation during iron-deficient anemia","volume":"91","author":"Rishi","year":"2016","journal-title":"Am J Hematol"},{"key":"2026050404514652300_bib33","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1053\/j.jrn.2012.08.004","article-title":"Malnutrition-inflammation score is associated with handgrip strength in nondialysis-dependent chronic kidney disease patients","volume":"23","author":"Amparo","year":"2013","journal-title":"J Ren Nutr"},{"key":"2026050404514652300_bib34","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1053\/j.jrn.2010.07.004","article-title":"Handgrip strength as a simple indicator of possible malnutrition and inflammation in men and women on maintenance hemodialysis","volume":"21","author":"Silva","year":"2011","journal-title":"J Ren Nutr"},{"key":"2026050404514652300_bib35","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00198-019-05137-w","article-title":"Low free T3 to free T4 ratio was associated with low muscle mass and impaired physical performance in community-dwelling aged population","volume":"31","author":"Kong","year":"2020","journal-title":"Osteoporos Int"},{"key":"2026050404514652300_bib36","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1016\/j.celrep.2015.11.005","article-title":"Ferritin-mediated iron sequestration stabilizes hypoxia-inducible factor-1alpha upon LPS activation in the presence of ample oxygen","volume":"13","author":"Siegert","year":"2015","journal-title":"Cell Rep"},{"key":"2026050404514652300_bib37","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1053\/j.gastro.2007.12.008","article-title":"Hypoxia-independent activation of HIF-1 by Enterobacteriaceae and their siderophores","volume":"134","author":"Hartmann","year":"2008","journal-title":"Gastroenterology"},{"key":"2026050404514652300_bib38","first-page":"975","article-title":"Hypoxia-inducible factor induces local thyroid hormone inactivation during hypoxic-ischemic disease in rats","volume":"118","author":"Simonides","year":"2008","journal-title":"J Clin Invest"},{"key":"2026050404514652300_bib39","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/j.1365-2796.2007.01865.x","article-title":"Clinical and biochemical implications of low thyroid hormone levels (total and free forms) in euthyroid patients with chronic kidney disease","volume":"262","author":"Carrero","year":"2007","journal-title":"J Intern Med"},{"key":"2026050404514652300_bib40","doi-asserted-by":"publisher","first-page":"h910","DOI":"10.1136\/bmj.h910","article-title":"The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting","volume":"350","author":"Roberts","year":"2015","journal-title":"BMJ"},{"key":"2026050404514652300_bib41","first-page":"e876","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2026050404514652300_bib42","doi-asserted-by":"publisher","first-page":"1195082","DOI":"10.3389\/fcvm.2023.1195082","article-title":"Circulating erythroferrone has diagnostic utility for acute decompensated heart failure in patients presenting with acute or worsening dyspnea","volume":"10","author":"Appleby","year":"2023","journal-title":"Front Cardiovasc Med"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfag075\/67280675\/sfag075.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/5\/sfag075\/67280675\/sfag075.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/5\/sfag075\/67280675\/sfag075.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T08:51:53Z","timestamp":1777884713000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfag075\/8512268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfag075","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,3,9]]},"article-number":"sfag075"}}